Kent James Weinhold, PhD

AddThis

Print

email this


Professor of Surgery
Professor of Immunology
Chief, Division of Surgical Sciences
Department / Division:
Surgery / Surgical Sciences
Address:
204 Surg Oncol Res Fac
Durham, NC 27710
Office Telephone:
(919) 684-5572
Training:
  • PhD, Thomas Jefferson University, 1979
Representative Publications:
  • Freel, SA; Lamoreaux, L; Chattopadhyay, PK; Saunders, K; Zarkowsky, D; Overman, RG; Ochsenbauer, C; Edmonds, TG; Kappes, JC; Cunningham, CK; Denny, TN; Weinhold, KJ; Ferrari, G; Haynes, BF; Koup, RA; Graham, BS; Roederer, M; Tomaras, GD. Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. Journal of Virology. 2010;84:4998-5006.  Abstract
  • Goonetilleke, N; Liu, MK; Salazar-Gonzalez, JF; Ferrari, G; Giorgi, E; Ganusov, VV; Keele, BF; Learn, GH; Turnbull, EL; Salazar, MG; Weinhold, KJ; Moore, S; CHAVI Clinical Core B, ; Letvin, N; Haynes, BF; Cohen, MS; Hraber, P; Bhattacharya, T; Borrow, P; Perelson, AS; Hahn, BH; Shaw, GM; Korber, BT; McMichael, AJ. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. Journal of Experimental Medicine. 2009;206:1253-1272.  Abstract
  • Murdoch, DM; Suchard, MS; Venter, WD; Mhlangu, P; Ottinger, JS; Feldman, C; Van Rie, A; Glencross, DK; Stevens, WS; Weinhold, KJ. Polychromatic immunophenotypic characterization of T cell profiles among HIV-infected patients experiencing immune reconstitution inflammatory syndrome (IRIS). AIDS Research and Therapy. 2009;6:16.  Abstract
  • Shen, X; Parks, RJ; Montefiori, DC; Kirchherr, JL; Keele, BF; Decker, JM; Blattner, WA; Gao, F; Weinhold, KJ; Hicks, CB; Greenberg, ML; Hahn, BH; Shaw, GM; Haynes, BF; Tomaras, GD. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. Journal of Virology. 2009;83:3617-3625.  Abstract
  • Spearman, P; Kalams, S; Elizaga, M; Metch, B; Chiu, YL; Allen, M; Weinhold, KJ; Ferrari, G; Parker, SD; McElrath, MJ; Frey, SE; Fuchs, JD; Keefer, MC; Lubeck, MD; Egan, M; Braun, R; Eldridge, JH; Haynes, BF; Corey, L; NIAID HIV Vaccine Trials Network. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine. 2009;27:243-249.  Abstract
  • Alam, SM; Scearce, RM; Parks, RJ; Plonk, K; Plonk, SG; Sutherland, LL; Gorny, MK; Zolla-Pazner, S; Vanleeuwen, S; Moody, MA; Xia, SM; Montefiori, DC; Tomaras, GD; Weinhold, KJ; Karim, SA; Hicks, CB; Liao, HX; Robinson, J; Shaw, GM; Haynes, BF. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. Journal of Virology. 2008;82:115-125.  Abstract
  • Gasper-Smith, N; Crossman, DM; Whitesides, JF; Mensali, N; Ottinger, JS; Plonk, SG; Moody, MA; Ferrari, G; Weinhold, KJ; Miller, SE; Reich, CF; Qin, L; Self, SG; Shaw, GM; Denny, TN; Jones, LE; Pisetsky, DS; Haynes, BF. Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. Journal of Virology. 2008;82:7700-7710.  Abstract
  • Gorse, GJ; Baden, LR; Wecker, M; Newman, MJ; Ferrari, G; Weinhold, KJ; Livingston, BD; Villafana, TL; Li, H; Noonan, E; Russell, ND; HIV Vaccine Trials Network. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine. 2008;26:215-223.  Abstract
  • Russell, ND; Graham, BS; Keefer, MC; McElrath, MJ; Self, SG; Weinhold, KJ; Montefiori, DC; Ferrari, G; Horton, H; Tomaras, GD; Gurunathan, S; Baglyos, L; Frey, SE; Mulligan, MJ; Harro, CD; Buchbinder, SP; Baden, LR; Blattner, WA; Koblin, BA; Corey, L; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. JAIDS: Journal of Acquired Immune Deficiency Syndromes. 2007;44:203-212.  Abstract
  • Mulligan, MJ; Russell, ND; Celum, C; Kahn, J; Noonan, E; Montefiori, DC; Ferrari, G; Weinhold, KJ; Smith, JM; Amara, RR; Robinson, HL; NIH/NIAID/DAIDS HIV Vaccine Trials Network. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Research and Human Retroviruses. 2006;22:678-683.  Abstract
  • Betts, MR; Exley, B; Price, DA; Bansal, A; Camacho, ZT; Teaberry, V; West, SM; Ambrozak, DR; Tomaras, G; Roederer, M; Kilby, JM; Tartaglia, J; Belshe, R; Gao, F; Douek, DC; Weinhold, KJ; Koup, RA; Goepfert, P; Ferrari, G. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proceedings of the National Academy of Sciences of USA. 2005;102:4512-4517.  Abstract
  • Kaplan, SS; Ferrari, G; Wrin, T; Hellmann, NS; Tomaras, GD; Gryszowka, VE; Fiscus, SA; Weinhold, KJ; Hicks, CB. Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance. AIDS Research and Human Retroviruses. 2005;21:13-16.  Abstract
  • Ferrari, G; Currier, JR; Harris, ME; Finkelstein, S; de Oliveira, A; Barkhan, D; Cox, JH; Zeira, M; Weinhold, KJ; Reinsmoen, N; McCutchan, F; Birx, DL; Osmanov, S; Maayan, S. HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians. Human Immunology. 2004;65:648-659.  Abstract
  • Ferrari, G; Neal, W; Ottinger, J; Jones, AM; Edwards, BH; Goepfert, P; Betts, MR; Koup, RA; Buchbinder, S; McElrath, MJ; Tartaglia, J; Weinhold, KJ. Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele. Journal of Immunology. 2004;173:2126-2133.  Abstract
  • Montefiori, DC; Metch, B; McElrath, MJ; Self, S; Weinhold, KJ; Corey, L; HIV Vaccine Trials Network. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. Journal of Infectious Diseases. 2004;190:1962-1969.  Abstract
  • Wright, PF; Mestecky, J; McElrath, MJ; Keefer, MC; Gorse, GJ; Goepfert, PA; Moldoveanu, Z; Schwartz, D; Spearman, PW; El Habib, R; Spring, MD; Zhu, Y; Smith, C; Flores, J; Weinhold, KJ; National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. Journal of Infectious Diseases. 2004;189:1221-1231.  Abstract
  • Sufka, SA; Ferrari, G; Gryszowka, VE; Wrin, T; Fiscus, SA; Tomaras, GD; Staats, HF; Patel, DD; Sempowski, GD; Hellmann, NS; Weinhold, KJ; Hicks, CB. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. Journal of Infectious Diseases. 2003;187:1027-1037.  Abstract
  • Demarest, JF; Jack, N; Cleghorn, FR; Greenberg, ML; Hoffman, TL; Ottinger, JS; Fantry, L; Edwards, J; O'Brien, TR; Cao, K; Mahabir, B; Blattner, WA; Bartholomew, C; Weinhold, KJ. Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. AIDS Research and Human Retroviruses. 2001;17:1333-1344.  Abstract